Designing small molecules to target cryptic pockets yields both positive and negative allosteric modulators by Hart, Kathryn M et al.




Designing small molecules to target cryptic pockets
yields both positive and negative allosteric
modulators
Kathryn M. Hart
Washington University School of Medicine in St. Louis
Katelyn E. Moeder
Washington University School of Medicine in St. Louis
Chris M. W. Ho
Washington University School of Medicine in St. Louis
Maxwell I. Zimmerman
Washington University School of Medicine in St. Louis
Thomas E. Frederick
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Hart, Kathryn M.; Moeder, Katelyn E.; Ho, Chris M. W.; Zimmerman, Maxwell I.; Frederick, Thomas E.; and Bowman, Gregory R.,




Kathryn M. Hart, Katelyn E. Moeder, Chris M. W. Ho, Maxwell I. Zimmerman, Thomas E. Frederick, and
Gregory R. Bowman
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5934
RESEARCH ARTICLE
Designing small molecules to target cryptic
pockets yields both positive and negative
allosteric modulators
Kathryn M. Hart1, Katelyn E. Moeder1, Chris M. W. Ho1, Maxwell I. Zimmerman1, Thomas
E. Frederick1, Gregory R. Bowman1,2*
1 Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis,
Missouri, United States of America, 2 Department of Biomedical Engineering, and Center for Biological
Systems Engineering, Washington University in St. Louis, St. Louis, Missouri, United States of America
* bowman@biochem.wustl.edu
Abstract
Allosteric drugs, which bind to proteins in regions other than their main ligand-binding or
active sites, make it possible to target proteins considered “undruggable” and to develop
new therapies that circumvent existing resistance. Despite growing interest in allosteric drug
discovery, rational design is limited by a lack of sufficient structural information about alter-
native binding sites in proteins. Previously, we used Markov State Models (MSMs) to identify
such “cryptic pockets,” and here we describe a method for identifying compounds that bind
in these cryptic pockets and modulate enzyme activity. Experimental tests validate our
approach by revealing both an inhibitor and two activators of TEM β-lactamase (TEM). To
identify hits, a library of compounds is first virtually screened against either the crystal struc-
ture of a known cryptic pocket or an ensemble of structures containing the same cryptic
pocket that is extracted from an MSM. Hit compounds are then screened experimentally
and characterized kinetically in individual assays. We identify three hits, one inhibitor and
two activators, demonstrating that screening for binding to allosteric sites can result in both
positive and negative modulation. The hit compounds have modest effects on TEM activity,
but all have higher affinities than previously identified inhibitors, which bind the same cryptic
pocket but were found, by chance, via a computational screen targeting the active site. Site-
directed mutagenesis of key contact residues predicted by the docking models is used to
confirm that the compounds bind in the cryptic pocket as intended. Because hit compounds
are identified from docking against both the crystal structure and structures from the MSM,
this platform should prove suitable for many proteins, particularly targets whose crystal
structures lack obvious druggable pockets, and for identifying both inhibitory and activating
small-molecule modulators.
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Introduction
Rational drug design based on a single protein structure captured, for instance, by x-ray crys-
tallography typically focuses on molecules that bind to and sterically block a key functional
site. Therefore, this approach is inapplicable to proteins that lack obvious druggable pockets or
scenarios where activation, rather than inhibition, is desired. However, proteins are not static
objects. They are ensembles of structures populated at equilibrium according to each state’s
thermodynamic stability. It is possible to access many of the alternative structures a protein
adopts by methods such as NMR [1] or molecular dynamics simulations [2]. Druggable pock-
ets that appear in these alternate structures, called cryptic pockets, present the opportunity to
design allosteric drugs, which bind to proteins in regions other than their main ligand-binding
or active sites and are known to have distinct benefits over drugs targeting active sites [3]. For
example, there is good reason to believe that activator compounds would prove efficacious
against diseases as diverse as cancer [4], liver disease [5] and diabetes [6]. While there are
examples of high-throughput experimental screens that have serendipitously identified com-
pounds that bind cryptic pockets [7] and screens designed specifically for finding allosteric
modulators [8], our goal is to develop a structure-based approach to rationally target cryptic
pockets in proteins for drug design.
As a proof of principle, we chose to target TEM β-lactamase (TEM). TEM is the enzyme
underlying one prominent mechanism of antibiotic resistance in pathogenic Gram-negative
bacteria [9]. It confers resistance against β-lactam antibiotics, such as penicillin, by hydrolyzing
them into inactive forms. Inhibiting this enzyme is one strategy for restoring the efficacy of β-
lactam antibiotics. Current therapies use either mechanism-based inhibitors, such as the natu-
ral product clavulanic acid, which irreversibly react with TEM’s active site serine, or transi-
tion-state analogs like boronic-acid derivatives [10]. Both types of inhibitors act by sterically
blocking the active site, preventing substrate from binding. TEMs that are resistant to these
competitive inhibitors have been identified in the clinic, heightening the urgency for new,
novel inhibitors that will not be susceptible to pre-existing forms of resistance.
We have previously employed Markov state models (MSMs) of TEM to identify cryptic
pockets that are not obvious in the ligand-free crystal structure of TEM [2,11]. An MSM is a
network representation of a protein’s energy landscape, consisting of nodes that represent
energy minima where the protein tends to dwell and the probabilities of transitioning between
these states. They are typically constructed from many independent molecular dynamics simu-
lations and provide a convenient coarse-graining of the data that enables practitioners to
quickly identify interesting features. After using MSMs to identify a number of cryptic pockets
in TEM [2], we tested them experimentally through a chemical modification technique target-
ing cysteine residues that become solvent exposed upon pocket opening [11]. There is evidence
that small molecules binding in these pockets, either through covalent attachment to the engi-
neered cysteine [11] or non-covalent interactions [7], act as inhibitors.
Here we describe a method for targeting cryptic pockets and apply it to TEM. First, we use
docking to screen a library of compounds against a cryptic pocket identified from our MSM.
Importantly, instead of targeting a single structure, we employ our recently developed Boltz-
mann-docking technique [12] to account for conformational heterogeneity in the structure of
a pocket. Then we use a high-throughput screen to experimentally test the highest scoring
compounds. Finally, we characterize the hit compounds in depth and use site-directed muta-
genesis to support our model that they bind in the cryptic pocket as designed. Using this
method, we identify one inhibitor and two activator compounds. The inhibitor has an
EC50 = 57 ± 3 μM, and while modest relative to TEM inhibitors used clinically, it represents
an improvement over inhibitors with Ki’s of 500 μM that were found by chance to bind this
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pocket [7]. While it is not obvious that activators of TEM would be clinically relevant, the abil-
ity to design activators could prove useful against other strategically chosen targets. Overall,
our results highlight the general utility of our approach for identifying both inhibitors and acti-
vator compounds.
Materials and methods
Protein structure selection for docking
Structures containing cryptic pockets were selected from our previously constructed MSM for
TEM [2]. A Python implementation of LIGSITE [13] was used to identify pocket volume ele-
ments within representative structures from each state in this MSM, where the grid step size
was set to 1.0 Å and the minimum number of protein-solvent-protein (minPSP) events was set
to 6. Contiguous pocket volume elements were grouped together into pockets. Pockets consist-
ing of less than 30 pocket elements (~30 Å3) were discarded. For each pocket, the set of struc-
tures containing that pocket was identified as follows: 1) the largest unclustered pocket is
selected as a new cluster center, 2) all pockets are assigned to the closest cluster center that is
within a specified distance cutoff (i.e. if the distance between a pocket’s center of mass and any
cluster center’s center of mass is not within the distance cutoff, it remains unassigned), and 3)
steps 1–2 are repeated until all pockets are assigned. Representative structures from the 15
most populated states (i.e. populations greater than or equal to 0.004% of the population) that
contained the known cryptic pocket were selected as targets for screening (see S1 Dataset). For
reference, 80% of the total states in the MSM have populations above this threshold, and it
eliminates about half of the states in which the cryptic pocket occurs.
Small molecule library source and preparation for docking
The compounds used in this work were obtained from “The NCI/DTP Open Chemical Repos-
itory” at http://dtp.nci.nih.gov. The database was filtered for compounds that obey Lipinski’s
rule of 5 [14], except a molecular weight cutoff of 400 g/mol was used. It was also purged of
reactive and promiscuous [15] and aggregation-prone [16] compounds resulting in a total of
12,695 compounds screened. The compounds were all>95% pure as certified by the supplier
(NCI DTP Discovery Services) and assumed to be racemic mixtures. The best-predicted bind-
ers were ordered from NCI for use in the in vitro activity assays. Compounds were dissolved in
100% dimethyl sulfoxide and stored at −20˚C. Four compounds could not be solubilized and
were not tested.
Docking
Docking against individual structures was performed with Surflex-dock [17]. The compound
structures were generated using the Concord module of SYBYL-X 2.1.1 and minimized using
the Tripos force field. Because SMILES strings from the NCI database do not specify stereo-
chemistry, this minimization procedure selects only the lowest energy isomer for docking. Sur-
flex-Dock receptor protomols were generated with a threshold of 0.5 and a bloat of 3.0. These
protomols were then used to screen various ligands for receptor complementarity. The Ham-
merhead scoring function [18] inherent to Surflex was used to score the resulting poses. The
default ‘-pgeom’ docking accuracy parameter set was used. Boltzmann-docking scores were
then calculated as the weighted-average of the scores for each state, using the equilibrium
probabilities of each state as their weights.
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Protein expression and purification
A variant of TEM containing the M182T substitution was used for these studies. The gene was
expressed from a pET24 vector (Life Technologies) using an OmpA signal sequence to target it
to the periplasm in BL21(DE3) Gold cells (Agilent Technologies).
Cells were induced with 1 mM IPTG at OD = 0.6 and grown at 18˚C for 15 h before har-
vesting. TEM β-lactamases were isolated from the periplasmic fraction using osmotic shock
lysis: Cells were resuspended in 30 mM Tris pH 8, 20% sucrose and stirred for 10 min at room
temperature. After centrifugation, the pellet was re-suspended in ice-cold 5 mM MgSO4 and
stirred for 10 min at 4˚C. After centrifugation, the supernatant was dialyzed against 20 mM
sodium acetate, pH 5.5 and purified using cation exchange chromatography (BioRad UNO-
sphere Rapid S column) and exchanged into storage buffer (20 mM Tris, pH 8.0) by size exclu-
sion chromatography (BioRad ENrich SEC 70 column).
Activity assays
A UV-vis plate-based assay was used to experimentally screen compounds identified in the vir-
tual screen. To each well of a 96-well plate was added 1 nM TEM, 2% DMSO, 10% glycerol
and 0.01% Triton X-100 in 50 mM potassium phosphate buffer at pH 7.0. Compounds were
tested in triplicate at concentrations of 500 nM, 50 μM and 100 μM. The reactions were initi-
ated by addition of 50 μM nitrocefin (Cayman Chemical Company), incubated at 25˚C and
followed by absorption at 482 nm for 25 seconds using a BioTek Synergy2 Multi-Mode Reader.
The enzyme and compound were pre-incubated for 5 minutes prior to addition of substrate.
Initial velocities were extracted by fitting the first 10 seconds to a linear equation. We define
hits as compounds that had: 1) dose-dependent activity, and 2) an impact greater than or equal
to 20% that of the internal control reactions on the same plate containing no compound.
Individual activity assays were performed in a Cary 60 UV-vis spectrometer (Agilent Tech-
nologies). For measuring TEM activity, each reaction contained 1–10 nM enzyme, 2% DMSO,
0.01% Triton X-100, 10% glycerol, 10–200 μM nitrocefin and 50–100 μM compound in 50
mM potassium phosphate buffer at pH 7.0. After the enzyme and ligand were incubated for 5
minutes at 25˚C, nitrocefin was added and the reaction was followed at 482 nm for 70 seconds.
Dose-response curves were acquired at 50 μM nitrocefin. Kinetic parameters (kcat and Km)
were determined by the Michaelis-Menten equation using initial velocity non-linear regres-
sion analysis in Kaleidagraph (Synergy Software, v 4.5). Data for compound 1 was fit by a two-
parameter activation model (Eq 1), fixing Km to the value from data taken in the absence of










Chymotrypsin reactions were followed at 410 nm using 30 nM enzyme and 200 μM N-suc-
cinyl-Ala-Ala-Pro-Phe p-nitroanilide at 25˚C. β-galactosidase reactions were followed at 420
nm using 4 nM enzyme and 1 mM 2-nitrophenyl β-D-galactopyranoside at 37˚C. All assays
were performed in triplicate in 50 mM potassium phosphate buffer, 0.01% Triton and 2%
DMSO at concentrations of substrate below their Km’s to ensure effects on either kcat or Km
would be detectable. Enzymes and substrates were purchased from Sigma-Aldrich.
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Results and discussion
Docking against the crystal structure of a cryptic pocket yields an
activator
To test our docking protocol and set a baseline for assessing the success of targeting structures
from our MSM, we first applied our docking approach to a crystal structure of a cryptic pocket.
Only through crystallization of TEM with an inhibitor from a screen was this cryptic pocket
revealed [7], as it is not present in the structure when ligand is not bound [20] (Fig 1a). Of the
Fig 1. Crystal structure of TEM’s cryptic pocket. (a) Structures of TEM crystallized in the absence of
ligands (blue ribbon, 1JWP) and presence of an inhibitor (magenta ribbon, 1PZO), which is removed to
highlight its cryptic binding pocket (yellow sphere). (b) A high-scoring, representative pose for compound 1
(cyan sticks).
https://doi.org/10.1371/journal.pone.0178678.g001
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12,695 compounds we screened in silico, we tested the 40 compounds with the highest docking
scores for their ability to modulate TEM activity in a high throughput plate-based assay, and
identified 5 hit compounds. Of these, 4 were eliminated due to aggregation or non-specific
effects (see Methods). The remaining compound 1 (Fig 1b) was further investigated in detail to
determine its effect on catalytic efficiencies and its dose dependence (Fig 2). The compound
increased TEM’s kcat/Km for nitrocefin by 52% (S1 Table). Aggregation at high concentration
prevented us from obtaining a saturated dose-dependence curve, but fitting initial velocities to
a mixed-activation model (Eq 1) results in a dissociation constant for the enzyme-substrate
complex, or Kact, of 162 ± 15 μM. Although our initial docking screen was performed using
Fig 2. Compound structures, dose-dependence curves and EC50s.
https://doi.org/10.1371/journal.pone.0178678.g002
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only the lowest-energy isomer depicted in Fig 2, our assays contained a racemic mixture. Com-
pound 1 contains two chiral centers, making a total of four possible isomers. We retroactively
docked the other three stereoisomers and found that they score similarly, adopting extended
conformations to fill the binding pocket (S1 Fig), which suggests they might all contribute to
the observed activity. If, however, only one isomer is active, then the dissociation constant
reported here likely underestimates the compound’s true affinity. While it may seem surpris-
ing to discover an activator during a screen against a pocket previously shown to bind an
inhibitor, there is precedent in the literature for compounds to bind to the same location on a
protein but have opposite effects on activity [21].
Docking against an ensemble of cryptic pocket structures yields an
activator and an inhibitor
Having successfully found an activator compound by docking against a crystal structure of the
known cryptic pocket, we wanted to test whether docking against an ensemble of pocket struc-
tures from our MSM is similarly able to identify novel modulators of TEM activity. Our previ-
ous work demonstrated that the cryptic pocket identified in the inhibitor-bound crystal
structure is also detectable in simulations of the protein in the absence of compound [2], allow-
ing us to compare our strategies using the same pocket. We docked the same library of com-
pounds described above against 15 structures from the simulation (Fig 3A). These structures
were chosen based on two criteria: first, they contained the known cryptic pocket; and second,
they are highly populated structures in the MSM (See methods). The most populated state in
our set of 15 structures is an order of magnitude more probable than the least populated state,
and we reasoned that a compound would require a higher affinity for a lowly populated state
than a highly populated state to be an equivalent hit. To account for the differences in popula-
tions, we employed a method we developed previously, called Boltzmann docking, to rank the
library of compounds. Boltzmann docking takes advantage of population information from
the MSM to generate a score that accounts for both interactions between the compound and
protein and the probability of the structure being docked against. Previously, we have shown
this approach can better predict substrate affinities than docking against single structures [12].
Available compounds with high Boltzmann-weighted docking scores against multiple struc-
tures were ordered from the NCI for screening in an in vitro plate-based assay. Out of 71 com-
pounds tested, 16 effected TEM activity and were subjected to further testing. Of these, 14
were eliminated due to aggregation or non-specific effects (see Methods). Of the two remain-
ing compounds, one (compound 2, Fig 3b) is an activator, increasing kcat/Km by 39% with an
EC50 of 63 ± 9 μM. The other (compound 3, Fig 3c) is an inhibitor, decreasing kcat/Km by 59%
with an EC50 of 57 ± 3 μM (Fig 2 and S1 Table). Compound 3 has one chiral center, so like
compound 1, we docked the alternative isomer for comparison (S1 Fig). The binding pocket
accommodates this isomer with a comparable score to our original hit. It is possible, however,
that the EC50 we report, which was measured using a racemic mixture, underestimates the
active compound’s affinity if one isomer is more active than the other.
We identify hit compounds with similar efficacies whether docking against the crystal
structure or structures from the MSM. Although the effects of the three hit compounds are
modest compared with true drug molecules with binding affinities in the 60–160 μM range,
they are an improvement over inhibitors identified by chance to bind this pocket, which are
closer to 500 μM [7]. Furthermore, we find it intriguing that docking against the same pocket
yielded both positive and negative modulators. In the future, it would be interesting to under-
stand why the effects of these compounds differ so markedly, with the ultimate objective of
being able to predict whether a compound will be an activator or inhibitor.
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Fig 3. (a) Crystal structure of TEM (blue ribbon, 1JWP) overlaid with 3 representative structures used in
Boltzmann docking (white ribbon) to highlight the cryptic pocket (yellow sphere). (b) A high-scoring,
representative pose for compound 2 (cyan sticks). (c) A high-scoring, representative pose for compound 3
(cyan sticks).
https://doi.org/10.1371/journal.pone.0178678.g003
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The effects of all hit compounds are specific
Many hit compounds identified by virtual or high throughput screening efforts are known to
act non-specifically, most commonly via aggregation-based mechanisms [22,23]. We took
several precautions at each stage to minimize and identify false positives. At the in silico screen-
ing level, we filtered the NCI/DTP library for reactive [15] and aggregation-prone [16] com-
pounds. The experimental screens were performed in the presence of 0.01% Triton-X, which is
below its critical micelle concentration (0.02%). Our hit compounds were also assayed individ-
ually in the absence of Triton-X to test for detergent-dependence, which is consistent with
non-specific aggregation-based mechanisms of action. Modulation by compounds 2 and 3 was
similar under all conditions (S2 Table). For compound 1, however, no activation was observed
in the absence of detergent. This is the opposite effect expected for an aggregation-based mech-
anism and suggests enhancing the solubility of the compound through addition of 0.01% Tri-
ton-X is important for its mode of action, supporting a model for specific binding to TEM.
Another hallmark of non-specific aggregation mechanisms is dependence on enzyme concen-
tration [24]. We measured each hit compound’s activity as a function of enzyme concentration
and observed the same modulating effects over a ten-fold range of concentrations for com-
pounds 2 and 3. Compound 1 has reduced effectiveness at the highest enzyme concentration
tested, so we further investigated potential non-specific effects by testing it against unrelated
enzymes. While general mechanisms for non-specific activation have not been thoroughly
investigated, it has been suggested that non-specific activators may act like detergents by inter-
fering with adsorption of protein to surfaces [25]. If this were the mechanism for compound 1,
or for our other hit compounds, then it should have similar effects on many other types of
enzymes. To test this idea, we chose two alternative enzymes with dissimilar structures and
activities from TEM, chymotrypsin and β-galactosidase. None of the hits had an impact on the
activity of either enzyme (S2 Table), again supporting the idea that the compounds act
specifically.
Eliminating key contacts in the binding pocket abrogates effects
We verified that our compounds were binding in the intended pocket by removing key protein
contacts, as predicted by our docking models, and measuring activity in the presence and
absence of compound (Fig 4). Variants lacking key contacts will have compromised binding
affinities, and thus their activities will be less effected by the compounds. Our docking suggests
multiple modes of binding for the compounds to the cryptic pocket, due in part to its greasy
character. The top ten docking poses for the compounds against all 15 states were evaluated
visually to identify recurrent contacts, particularly potential hydrogen bonds and electrostatic
interactions that could be targeted by mutagenesis.
For compound 1, all of the sidechains in the cryptic pocket with significant contacts are
hydrophobic and form van der Waals interactions with aliphatic regions of the compound.
We chose to mutate Leu220 to Asn, which is isosteric but increases the polarity of this residue
and thus compromises its ability to interact with compound (Fig 4a). It is also a residue pre-
dicted to form significant contacts with each possible isomer (S1 Fig), so we would expect to
observe an effect even if multiple isomers are active in our assay. As predicted, activity of the
L220N variant is the same both in the presence and absence of compound 1, as demonstrated
by the fact that the kcat’s and Km’s measured under both conditions are within error (Fig 4a
and S1 Table). This suggests that compound no longer binds in the presence of the L220N sub-
stitution. Therefore, we conclude the compound is binding in the cryptic pocket as predicted
and that L220 is a key residue for stabilizing the interaction.
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To determine whether compounds 2 and 3 were binding in the predicted cryptic pocket, we
made variants of TEM lacking key contacts revealed by our docking models (Fig 4b and 4c).
Again, most of the sidechains in the cryptic pocket are hydrophobic and form van der Waals
interactions with aliphatic regions of the compounds. To minimize perturbation to the protein
structure, however, we chose to substitute the residues predicted to form hydrogen bonds or
electrostatic interactions with the compounds.
To test the binding of the activator, compound 2, we substituted Thr265 with a Val to elimi-
nate its ability to hydrogen bond to the compound’s morpholinyl oxygen (Fig 4b). Compound
2 increases activity of T265V by 16%, which is about half its effect on TEM without the substi-
tution (S1 Table). While the hydrogen bond clearly contributes to binding, removing it does
not completely eliminate binding. Regardless, the reduced efficacy of compound 2 against
T265V supports our hypothesis that the activator binds in the cryptic pocket, as intended.
Mutational data also support our hypothesis that the inhibitor, compound 3, binds in the
intended pocket. In many of its top poses, and for both isomers (S1 Fig), the negatively charged
nitro functional group of the inhibitor, compound 3, is poised to form a favorable electrostatic
Fig 4. Michaelis-Menten plots for TEM and variants without compound (blue dotted line) and with 100 μM compounds (red
solid line) (a) 1, (b) 2 or (c) 3. Error bars are standard deviations. Insets highlight the key contact residues that are substituted in the
variants and their interactions with the docked compounds. Compound 1 is shown in cyan spheres to emphasize van der Waals contacts
with Leu220, whereas compounds 2 and 3 are shown in cyan sticks to highlight hydrogen bond and electrostatic interactions,
respectively. Hydrogen bond is indicated with dashed black line.
https://doi.org/10.1371/journal.pone.0178678.g004
Designing small molecules to target cryptic pockets yields both positive and negative allosteric modulators
PLOS ONE | https://doi.org/10.1371/journal.pone.0178678 June 1, 2017 10 / 13
interaction with Arg244 (Fig 4c). We tested the effect of compound 3 on TEM R244S with the
prediction that it would be less able to inhibit the enzyme. Interestingly, Arg244 is a critical
residue for substrate binding, and substitutions at position 244 are known to severely compro-
mise activity [26], which suggests a mode of action for our inhibitor. We observe that R244S is
much less active than TEM (S1 Table), and the enzyme does not saturate under the conditions
of our assay (Fig 4c). Nonetheless, we reasoned that our approach for testing the binding loca-
tion should apply even in this less active variant, because we can still compare kcat/Km in the
presence and absence of compound 3. Indeed, we observe no inhibition by compound 3 for
R244S (S1 Table), suggesting the compound binds in the cryptic pocket and that the electro-
static interaction is formed and important for binding.
Conclusions
Cryptic pockets are a general feature of many protein folds [2]. Designing drugs that bind
them creates opportunities for identifying activator compounds and targeting proteins previ-
ously considered “undruggable.” Previously, we demonstrated that a cryptic pocket identified
in TEM is also detectable in MSMs of the protein built from molecular dynamics simulations
run in the absence of compound [2,11]. Here, we identify small molecule modulators of TEM
activity using both crystal structures and conformations from our computational model, show-
ing that either is a suitable target for virtual screening. Out of 111 compounds, we identify 21
that modulate enzyme activity in our high-throughput assay (19% hit rate). After eliminating
18 compounds due to aggregation or non-specific effects, we are left with 3 true hit com-
pounds—two activators and one inhibitor. Mutational analysis suggests these compounds
bind in the pocket as designed. Our results suggest it is possible to extend our methodology to
many protein targets, even those lacking crystal structures of cryptic pockets.
Supporting information
S1 Dataset. TEM structures against which the library of compounds was docked.
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S1 Table. Michaelis-Menten kinetic parameters for TEM β-lactamase variants with and
without compounds 1, 2 and 3.
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S2 Table. Tests for non-specific activity of compounds 1, 2 and 3.
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S1 Fig. Docking alternative isomers of (a) compound 1 and (b) compound 3. Residues tar-
geted in mutagenesis studies are highlighted in (a) spheres or (b) sticks, and docked com-
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